Trials / Unknown
UnknownNCT03793725
A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC
A Phase II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Yanqiao Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma. This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a preoperative treatment of unresectable HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1210 | Anti-PD-1 Antibody |
| DRUG | Apatinib | Anti-angiogenic drugs |
Timeline
- Start date
- 2019-01-30
- Primary completion
- 2020-01-30
- Completion
- 2021-01-30
- First posted
- 2019-01-04
- Last updated
- 2019-01-04
Source: ClinicalTrials.gov record NCT03793725. Inclusion in this directory is not an endorsement.